Share this video  

ASCO 2020 | CheckMate 9LA study: nivo + ipi in NSCLC

Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, highlights data coming from the CheckMate 9LA study which evaluated nivolumab in combination with ipilimumab + 2 cycles of platinum-doublet chemotherapy vs 4 cycles of chemotherapy as first-line treatment for stage IV/reccurent non-small cell lung cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology),